Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
Khalaf DJ, Sunderland K, Eigl BJ, Kollmannsberger CK, Ivanov N, Finch DL, Oja C, Vergidis J, Zulfiqar M, Gleave ME, Chi KN. Khalaf DJ, et al. Among authors: vergidis j. Eur Urol. 2019 Jun;75(6):940-947. doi: 10.1016/j.eururo.2018.12.015. Epub 2018 Dec 24. Eur Urol. 2019. PMID: 30591354 Clinical Trial.
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN. Annala M, et al. Among authors: vergidis j. Cancer Discov. 2018 Apr;8(4):444-457. doi: 10.1158/2159-8290.CD-17-0937. Epub 2018 Jan 24. Cancer Discov. 2018. PMID: 29367197 Clinical Trial.
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, Zulfiqar M, Sunderland K, Azad AA, Kollmannsberger CK, Eigl BJ, Noonan K, Wadhwa D, Attwell A, Keith B, Ellard SL, Le L, Gleave ME, Wyatt AW, Chi KN. Khalaf DJ, et al. Among authors: vergidis j. Lancet Oncol. 2019 Dec;20(12):1730-1739. doi: 10.1016/S1470-2045(19)30688-6. Epub 2019 Nov 11. Lancet Oncol. 2019. PMID: 31727538 Clinical Trial.
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
Khalaf DJ, Aragón IM, Annala M, Lozano R, Taavitsainen S, Lorente D, Finch DL, Romero-Laorden N, Vergidis J, Cendón Y, Oja C, Pacheco MI, Zulfiqar M; PROREPAIR-B investigators; Gleave ME, Wyatt AW, Olmos D, Chi KN, Castro E. Khalaf DJ, et al. Among authors: vergidis j. Ann Oncol. 2020 Sep;31(9):1186-1197. doi: 10.1016/j.annonc.2020.06.006. Epub 2020 Jun 20. Ann Oncol. 2020. PMID: 32574722 Free article. Clinical Trial.
Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition.
Annala M, Taavitsainen S, Khalaf DJ, Vandekerkhove G, Beja K, Sipola J, Warner EW, Herberts C, Wong A, Fu S, Finch DL, Oja CD, Vergidis J, Zulfiqar M, Eigl BJ, Kollmansberger CK, Nykter M, Gleave ME, Chi KN, Wyatt AW. Annala M, et al. Among authors: vergidis j. Clin Cancer Res. 2021 Aug 15;27(16):4610-4623. doi: 10.1158/1078-0432.CCR-21-1625. Epub 2021 Jun 3. Clin Cancer Res. 2021. PMID: 34083234
Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study.
Soleimani M, Zou K, Sunderland K, Struss W, Eigl BJ, Nappi L, Kollmannsberger CK, Finch D, Noonan K, Vergidis J, Zulfiqar M, Chi KN, Khalaf DJ. Soleimani M, et al. Among authors: vergidis j. Eur J Cancer. 2021 Jul;152:215-222. doi: 10.1016/j.ejca.2021.05.003. Epub 2021 Jun 12. Eur J Cancer. 2021. PMID: 34130153
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.
Fonseca NM, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha AJ, Kollmannsberger C, Kwan EM, Parekh K, Schönlau E, Bernales CQ, Donnellan G, Ng SWS, Sumiyoshi T, Vergidis J, Noonan K, Finch DL, Zulfiqar M, Miller S, Parimi S, Lavoie JM, Hardy E, Soleimani M, Nappi L, Eigl BJ, Kollmannsberger C, Taavitsainen S, Nykter M, Tolmeijer SH, Boerrigter E, Mehra N, van Erp NP, De Laere B, Lindberg J, Grönberg H, Khalaf DJ, Annala M, Chi KN, Wyatt AW. Fonseca NM, et al. Among authors: vergidis j. Nat Commun. 2024 Feb 28;15(1):1828. doi: 10.1038/s41467-024-45475-w. Nat Commun. 2024. PMID: 38418825 Free PMC article.
Cost-effectiveness of therapies for melanoma.
Johnston KM, McPherson E, Osenenko K, Vergidis J, Levy AR, Peacock S. Johnston KM, et al. Among authors: vergidis j. Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):229-42. doi: 10.1586/14737167.2015.1017563. Epub 2015 Feb 23. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25703441 Review.
13 results